Laura Brass
Direttore/Membro del Consiglio presso Immunitas Therapeutics, Inc.
Provenienza dei contatti di primo grado di Laura Brass
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
19
| Private Company | Investment Managers | 19 |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.
15
| Holding Company | Medical/Nursing Services | 15 |
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA.
8
| Holding Company | Biotechnology | 8 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd
7
| Subsidiary | Investment Managers | 7 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Laura Brass tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ANNEXON, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| GALERA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Potenza Therapeutics, Inc.
 Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chief Operating Officer | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Stanford University | College/University | Doctorate Degree Graduate Degree | |
| University of Pennsylvania | College/University | Masters Business Admin Doctorate Degree | |
| Boston University | College/University | Masters Business Admin Undergraduate Degree Graduate Degree | |
| University of Cambridge | College/University | Undergraduate Degree Graduate Degree | |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor Corporate Officer/Principal | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Director of Finance/CFO | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Vermont | College/University | Undergraduate Degree Doctorate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree | |
| AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Director/Board Member Director/Board Member | |
| ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| ONCORUS, INC. | Biotechnology | Chief Executive Officer Director/Board Member | |
eGenesis, Inc.
 eGenesis, Inc. Miscellaneous Commercial ServicesCommercial Services eGenesis, Inc. operates research platform to deliver human transplantable cells, tissues, and organs grown in pigs. It uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation. The company was founded by George M. Church, Yang Luhan, Prashant Mali, Geoff Mackay and Guell Marc in 2015 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member Founder Director/Board Member | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Founder | |
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital LLC (Agent Capital) is a venture capital firm founded in 2017 by Geeta Vemuri. The firm is headquartered in Waltham, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
CODA Biotherapeutics, Inc.
 CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology CODA Biotherapeutics, Inc. engages in the development of chemo genetic neuromodulation platform for the treatment of severe neurological disorders. The company was founded by Mitchell H. Finer, Allan Basbaum, Nicholas Boulis, Joseph Glorioso III and Kenneth P. Greenberg in 2014 and is headquartered in South San Francisco, CA. | Medical Specialties | Director/Board Member Founder Director/Board Member | |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| TSCAN THERAPEUTICS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member Founder Director/Board Member | |
Khloris Biosciences, Inc.
 Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member Chief Operating Officer Chief Operating Officer | |
Leaps by Bayer
 Leaps by Bayer Investment ManagersFinance Leaps by Bayer is venture investment unit of Bayer AG (Xetra: BAYN) founded in 2015. The firm is headquartered in Leverkusen, Germany. | Investment Managers | Private Equity Investor Director/Board Member | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Director/Board Member Director of Finance/CFO Director/Board Member Chief Operating Officer | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Founder Director of Finance/CFO Corporate Officer/Principal | |
| PYXIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Director of Finance/CFO Private Equity Investor Private Equity Investor | |
Vesigen, Inc.
 Vesigen, Inc. BiotechnologyHealth Technology Vesigen, Inc. develops groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CARISMA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member Director/Board Member | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Executive Officer | |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer |
Statistiche
Distribuzione geografica
| Stati Uniti | 42 |
| Germania | 5 |
| Svizzera | 4 |
| Israele | 2 |
| Regno Unito | 2 |
Settori
| Health Technology | 27 |
| Consumer Services | 13 |
| Finance | 7 |
| Commercial Services | 6 |
| Retail Trade | 2 |
Posizioni
| Director/Board Member | 393 |
| Corporate Officer/Principal | 107 |
| Independent Dir/Board Member | 67 |
| Founder | 58 |
| Private Equity Investor | 55 |
Contatti più connessi
| Insiders | |
|---|---|
| Thomas Woiwode | 39 |
| Jürgen Eckhardt | 34 |
| Geeta S. Vemuri | 33 |
| Christoph Westphal | 32 |
| Florent Gros | 28 |
| Edward Hurwitz | 27 |
| David Stack | 27 |
| Mitchell Finer | 26 |
| Briggs Morrison | 26 |
| Nilesh Kumar | 26 |
| Jim Scopa | 26 |
| Pablo Cagnoni | 24 |
| Thomas Dyrberg | 24 |
| Campbell Murray | 23 |
| Anthony Adam Rosenberg | 23 |
- Borsa valori
- Insiders
- Laura Brass
- Connessioni Società